Original Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Mar 28, 2010; 16(12): 1473-1481
Published online Mar 28, 2010. doi: 10.3748/wjg.v16.i12.1473
Figure 1
Figure 1 Synergistic effects and CDI of Melatonin and Doxorubicin on HepG2 and Bel-7402 cells. HepG2 cells (A) and Bel-7402 cells (C) were treated with 10-8, 10-7, 10-6 and 10-5 mol/L Melatonin and 0.31, 0.63, 1.25 and 2.50 g/L Doxorubicin for 48 h; CDI values of the combination group in HepG2 cells (B) and Bel-7402 cells (D). Data are presented as mean ± SE (error bar) of triplicate cultures. aP < 0.05, bP < 0.01 vs Dox treated alone.
Figure 2
Figure 2 Effects of Melatonin and/or Doxorubicin on apoptosis of HepG2. A: Morphological changes of HepG2 cells treated with Mel and Dox. a: Untreated cells; b: 10-5 mol/L Mel; c: 1.25 mg/L Dox; d: 10-5 mol/L Mel plus 1.25 mg/L Dox; B: Percentage of apoptotic cells by TUNEL assay. Data are presented as mean ± SD (error bar) of triplicate cultures. fP < 0.01 vs control, hP < 0.01 vs Dox treated alone; C: Apoptotic cells determined by FCM assay. a: Untreated cells; b: 10-5 mol/L Mel; c: 1.25 mg/L Dox; d: 10-5 mol/L Mel plus 1.25 mg/L Dox.
Figure 3
Figure 3 Effects of Melatonin and/or Doxorubicin on apoptosis of Bel-7402. A: Morphological changes of Bel-7402 cells treated with Mel and Dox. a: Untreated cells; b: 10-5 mol/LMel; c: 2.5 mg/L Dox; d: 10-5 mol/L Mel plus 2.5 mg/L Dox; B: Percentage of apoptotic cells by TUNEL test. Data are presented as mean ± SD (error bar) of triplicate cultures. eP < 0.05, fP < 0.01 vs control, hP < 0.01 vs Dox treated alone; C: Apoptotic cells determined by FCM assay. a: Untreated cells; b: 10-5 mol/L Mel; c: 2.5 mg/L Dox; d: 10-5 mol/L Mel plus 2.5 mg/L Dox.
Figure 4
Figure 4 Effect of Melatonin and/or Doxorubicin on the expression of Bcl-2 (A) and Bax (B) in HepG2 cells, the quantitative analysis (C) of Bcl-2 and Bax. Quantitative analysis of Bcl-2 and Bax, expression by Biological Image Analysis System. Data are presented as mean ± SD (error bar). a: Untreated cells; b: 10-5 mol/L Mel; c: 1.25 mg/L Dox; d: 10-5 mol/L Mel plus 1.25 mg/L Dox. S-P (× 400). fP < 0.01 vs control of Bcl-2, hP < 0.01 vs control of Bax.
Figure 5
Figure 5 Effect of Melatonin and/or Doxorubicin on the expression of Bcl-2 (A) and Bax (B) in Bel-7402 cells, the quantitative analysis (C) of Bcl-2 and Bax. Quantitative analysis of Bcl-2 and Bax, expression by Biological Image Analysis System. Data are presented as mean ± SD (error bar). a: Untreated cells; b: 10-5 mol/L Mel; c: 2.5 mg/L Dox; d: 10-5 mol/L Mel plus 2.5 mg/L Dox. S-P (× 400). fP < 0.01 vs control of Bcl-2, hP < 0.01 vs control of Bax.
Figure 6
Figure 6 Effect of Melatonin and/or Doxorubicin on the expression of Casepase-3 in HepG2 (A) and Bel-7402 cells (B), and the quantitative analysis (C) of Caspase-3 expression. A: (a) Untreated cells; (b) 10-5 mol/LMel; (c) 1.25 mg/L Dox; (d) 10-5 mol/L Mel plus 1.25 mg/L Dox; B: (a) Untreated cells; (b) 10-5 mol/L Mel; (c) 2.5 mg/L Dox; (d) 10-5 mol/L Mel plus 2.5 mg/L Dox. S-P (× 400); C: Quantitative analysis of Caspase-3 expression by Biological Image Analysis System. Data are presented as mean ± SD (error bar). fP < 0.01 vs control of Caspase-3, hP < 0.01 vs Dox alone.